Stopping blood pressure medication safely: a UK guide
When antihypertensive medication can safely be stopped or reduced in the UK, what NICE says, which drugs need tapering, and what to monitor after stopping.
Read article →
Clinical Articles
Practical guides and clinical commentary
Evidence-led articles on stopping medication, understanding your data, and what the research actually means in practice.
Stopping GLP-1 medication safely: a UK guide
How to stop Mounjaro, Wegovy or Ozempic safely in the UK: what to monitor, which other medications need reviewing, and what NICE guidance says about stopping.
Read article →Stopping levothyroxine safely: a UK guide
When levothyroxine can be safely stopped or reduced in the UK, how to test whether the original indication still holds, and what NICE and the BTA say.
Read article →Stopping PPIs safely: a UK guide
How to stop proton pump inhibitors safely in the UK: managing rebound acid, step-down strategies, and when long-term PPI use is and is not justified.
Read article →Stopping SSRIs safely: a UK guide
How to stop SSRIs safely in the UK: what NICE and the RCGP say about tapering, how to distinguish withdrawal from relapse, and when to involve your GP.
Read article →Stopping statins safely: a UK guide
When stopping statins is clinically appropriate in the UK, what the evidence shows about cardiovascular risk, and how to approach the decision safely.
Read article →GLP-1 exit plan: what a proper review should include
What a clinical GLP-1 exit review should actually cover — the questions, the data, the medications, and the written 12-week plan that changes outcomes.
Read article →Stopping GLP-1s after reaching target weight
Reaching target weight on GLP-1 medication feels like success — but stopping at that point carries predictable risks that most patients are not told about.
Read article →Private GLP-1 prescribing: what follow-up is often missing
Private GLP-1 prescribing often omits the follow-up that changes outcomes. Here is what good clinical oversight looks like and what to do if yours has been lacking.
Read article →How long should you stay on GLP-1 medication?
How long to stay on Mounjaro or Wegovy is a clinical question, not a personal one. What the evidence says about duration, stopping criteria, and who benefits from long-term treatment.
Read article →GLP-1s and alcohol: why appetite is not the only signal
GLP-1 medication blunts alcohol interest in many patients. Why that happens, what it means for drinking patterns, and what to expect when the medication changes.
Read article →Mounjaro plateau: stop, increase, maintain, or rethink?
What a weight plateau on Mounjaro actually means and the four clinical options: increase the dose, maintain, stop, or rethink the approach entirely.
Read article →Stopping Mounjaro or Wegovy: What the BMJ Paper Really Shows
A new BMJ systematic review of 37 studies and 9,341 adults found weight regain of 0.4 kg per month after stopping weight-loss medication — with cardiometabolic markers drifting back within 1.4 years. Here is what that means, why it happens, and what a proper exit strategy actually looks like.
Read article →Weight regain after semaglutide: physiology, not failure
Why weight comes back after stopping Wegovy or Ozempic is not a character question. Here is the biology, what the trials show, and what a realistic plan looks like.
Read article →
Stopping GLP-1 Drugs: What the New BMJ Medicine Paper Really Shows
The new BMJ Medicine paper on GLP-1 discontinuation is not just about weight regain. In higher-risk patients, stopping may mean surrendering cardiovascular protection. A calm, clinical reading of what it actually found.
Read article →What to ask your doctor before stopping Wegovy
The specific questions worth raising with your doctor before stopping Wegovy — covering blood pressure, blood tests, diabetes, tapering, and what a proper exit plan includes.
Read article →Should I taper Mounjaro or stop suddenly?
The clinical case for tapering Mounjaro versus stopping suddenly: what the evidence shows, when tapering makes sense, and what actually determines outcomes.
Read article →What blood tests matter before stopping GLP-1 medication?
Which blood tests to check before stopping Mounjaro, Wegovy or Ozempic — and what the results should change about your stopping plan.
Read article →CagriSema: What the REDEFINE Trials Actually Mean
A plain-English summary of REDEFINE 1 and REDEFINE 2: what cagrilintide-semaglutide combination therapy showed and what it means in practice.
Read article →ESSENCE Trial Summary: Semaglutide and MASH
A clear summary of ESSENCE, the phase 3 trial that gave semaglutide histologic evidence in metabolic dysfunction-associated steatohepatitis with fibrosis.
Read article →FLOW Trial Summary: Semaglutide and Chronic Kidney Disease
A clear summary of FLOW, which moved semaglutide into the kidney outcomes conversation and showed hard renal benefits in type 2 diabetes with CKD.
Read article →Awiqli and Insulin Icodec: Why Once-Weekly Basal Insulin Matters
A plain-English review of insulin icodec and Awiqli: what the trial showed, what approval means, and who might benefit.
Read article →Maridebart Cafraglutide: Does Once-Monthly Dosing Change the Game?
A plain-English review of the phase 2 maridebart cafraglutide trial: what monthly dosing achieved for obesity, and what remains uncertain.
Read article →Oral Semaglutide for Obesity: What OASIS 1 Actually Showed
A plain-English summary of OASIS 1: how much weight oral semaglutide produced, who it applied to, and why the route of administration question is more complicated than most coverage suggests.
Read article →OASIS 1 Trial Summary: Oral Semaglutide for Obesity
OASIS 1 took oral semaglutide for obesity from novelty to plausibility. Here is what the trial showed and what route of administration actually changes.
Read article →Orforglipron Phase 2: Why the Early Obesity Data Mattered
A plain-English review of the orforglipron phase 2 obesity trial: what the early data showed, why it mattered, and what remained uncertain.
Read article →Orforglipron Phase 3: What the Pivotal Obesity Data Changed
A plain-English review of the orforglipron phase 3 obesity trial: what the pivotal data showed and what it still did not answer.
Read article →Retatrutide Phase 2: Why Triple Agonists Changed the Mood of the Field
A plain-English review of the retatrutide phase 2 trial: what triple agonism produced and why the field took notice.
Read article →SELECT Trial Summary: Semaglutide and Cardiovascular Risk
A clear summary of SELECT, the landmark trial that moved obesity pharmacotherapy from a weight discussion into an outcomes discussion.
Read article →Oral Semaglutide and Cardiovascular Outcomes: What SOUL Means
A clear summary of SOUL: what oral semaglutide did for cardiovascular outcomes, who the trial applied to, and what it did not prove.
Read article →STEP-HFpEF Trial Summary: Semaglutide for Obesity-Related HFpEF
STEP-HFpEF brought obesity medicine into a syndrome that has long frustrated both patients and cardiologists. Here is what it showed and what it means.
Read article →Higher-Dose Semaglutide: What STEP UP Actually Added
A plain-English review of STEP UP: what higher-dose semaglutide achieved, what it may offer beyond 2.4 mg, and what remains uncertain.
Read article →SUMMIT Trial Summary: Tirzepatide for HFpEF and Obesity
SUMMIT pushed the obesity-HFpEF story beyond symptom relief toward clinical events. Here is what it showed and how it differs from STEP-HFpEF.
Read article →SURMOUNT-5 Trial Summary: Tirzepatide vs Semaglutide
A clear summary of SURMOUNT-5, the head-to-head obesity trial comparing tirzepatide with semaglutide, and what the result really means in practice.
Read article →SURPASS-2: The Head-to-Head Trial That Changed Expectations
A plain-English review of SURPASS-2: what tirzepatide did against semaglutide in type 2 diabetes and why the trial mattered.
Read article →SURPASS-CVOT: What Tirzepatide Did, and Did Not, Prove on Cardiovascular Outcomes
A plain-English review of SURPASS-CVOT: the tirzepatide cardiovascular result, what noninferiority meant, and why the trial still matters.
Read article →Why GLP-1 exit is not just a willpower problem
Stopping GLP-1 medication and regaining weight is not a failure of willpower. Here is the biology of why it happens and what that means for planning.
Read article →Muscle loss on GLP-1s: what matters and what is exaggerated
The evidence on lean mass loss during GLP-1 treatment: what is real, what is exaggerated, why it matters for long-term outcomes, and what actually helps.
Read article →
Why GLP-1 Drugs Work Better for Some People Than Others
A contrarian look at why GLP-1 drugs work differently, what the new genetics paper actually shows, and what patients should do with that information.
Read article →
STEP 1 Trial Summary: What Semaglutide Actually Showed
A plain-English summary of STEP 1: how much weight semaglutide produced, who the trial applied to, and what it did not prove.
Read article →
SURMOUNT-1 Trial Summary: What Tirzepatide Actually Showed
A plain-English summary of SURMOUNT-1: how effective tirzepatide was in obesity, who the study applied to, and what it still did not answer.
Read article →
What Happens When Tirzepatide Is Stopped? What SURMOUNT-4 Showed
A clear summary of SURMOUNT-4: what happened when tirzepatide was continued, what happened when it was withdrawn, and why that matters for maintenance planning.
Read article →
What Happens When Semaglutide Is Stopped? What STEP 4 Showed
A clear, evidence-led summary of STEP 4: what happened when semaglutide was continued, what happened when it was stopped, and why that matters clinically.
Read article →Blood pressure after weight loss: do medicines need reviewing?
Significant weight loss frequently reduces blood pressure enough to make existing antihypertensive medication excessive. Here is when to check and what to do.
Read article →
Foundayo: What Lilly's New Weight Loss Pill Really Means
Foundayo is Lilly's new oral GLP-1 pill for weight loss. Here is what it does, how it compares, side effects, and why convenience is not the whole story.
Read article →GLP-1 constipation, reflux and nausea: when to worry
GLP-1 side effects explained clinically: what is normal, what needs review, and which symptoms require urgent assessment.
Read article →
Retatrutide Phase 3 Diabetes Results: What They Actually Show
Retatrutide's phase 3 diabetes data look strong on A1C and weight loss. Here is what the trial showed, what most coverage misses, and what patients should do now.
Read article →How to stop weight-loss injections safely
A clinical guide to stopping Mounjaro, Wegovy or Ozempic: what to do before the last dose, what to monitor, and how to reduce regain risk.
Read article →Appetite returning after GLP-1 medication
Why appetite comes back after stopping Mounjaro, Wegovy or Ozempic — and what to do about food noise, cravings and hunger before weight starts to move.
Read article →Mounjaro maintenance dose: what patients should understand
What the evidence says about staying on Mounjaro long-term, whether a lower dose can maintain results, and the clinical reality of tirzepatide maintenance.
Read article →Do you regain weight after stopping Ozempic?
The clinical answer: most people regain weight after stopping Ozempic. Here is what the evidence shows, why it happens, and what actually reduces the risk.
Read article →Coming off Wegovy: what to expect
What actually happens when you stop Wegovy: appetite timeline, weight regain evidence, blood pressure implications, and what a proper off-ramp plan looks like.
Read article →
Coming Off Mounjaro: What to Expect When Stopping Tirzepatide
A week-by-week guide to stopping Mounjaro. What happens when tirzepatide clears your system, why weight regain is common, and what a proper off-ramp plan looks like.
Read article →
SSRI Withdrawal vs Relapse: How to Tell the Difference
A research-heavy guide to distinguishing SSRI withdrawal from depressive relapse. What the evidence says, where the mainstream story falls short, and a more useful clinical framework.
Read article →
Coming Off Wegovy and Ozempic: What to Expect When You Stop Semaglutide
The evidence-backed guide to stopping semaglutide. What happens to appetite, weight, and cardiometabolic markers after you stop, why rebound happens, and what a proper off-ramp actually looks like.
Read article →